Skip to Content

Mitragynine Takes a Different Route to Pain Relief Than Morphine

Author: Adrian S. Siregar, Ph.D. | Editor-in-Chief: Sandy Akbar Nusantara, S.T., M.B.A.
November 18, 2026 by
Mitragynine Takes a Different Route to Pain Relief Than Morphine
MARKHERB, MarkHerb Indonesia

In this mouse study, purified mitragynine (>99%) was injected directly into the brain and tested alongside selective receptor blockers, to identify which opioid receptors it acts on.

The problem

Pain relief is one of medicine’s oldest challenges. Morphine and related opioids work well, but they also cause serious side effects, tolerance, and dependence. This pushes scientists to look for compounds that relieve pain through different, more selective routes.

Opioids act on receptors in the nervous system. There are several types, mainly mu (μ), delta (δ), and kappa (κ), and each shapes pain signaling differently. A compound that acts on a different mix of these receptors than morphine could behave differently. Mitragynine is the main alkaloid in the leaves of Mitragyna speciosa, a plant traditionally used in Thailand. It was known to have opioid-like pain-relieving effects. Which receptors it uses in the brain, and whether they match morphine’s, remained an open question. Without a purified, well-defined compound like mitragynine, that question can’t be answered cleanly. Crude plant material contains many alkaloids, so its effects can’t be pinned on any single one.

The study

Researchers at Toyama Medical and Pharmaceutical University and Chiba University used purified mitragynine, injected directly into the brain ventricles of mice. They compared it with morphine and with a κ-receptor activator (U50,488H) as references. The team then added selective blockers for each receptor type: cyprodime and naloxonazine for μ, naltrindole for δ, and nor-binaltorphimine for κ. Pain responses were measured with two standard tests, a tail-pinch test (mechanical pain) and a hot-plate test (heat pain).

Mitragynine’s effects were reduced by both the μ-receptor blockers and the δ-receptor blocker. Morphine’s effects were reduced by the μ blockers only, not by the δ blocker. The κ-receptor blocker only partly affected mitragynine, in the tail-pinch test but not the hot-plate test. The authors read this as indirect rather than direct κ involvement. Because mitragynine was purified, these differences could be attributed to the compound itself, not to a mixture of plant constituents.

Mitragynine’s pain-relieving action in the brain is mainly mediated by μ- and δ-opioid receptors, and its receptor profile differs from morphine’s. This answers the question posed at the outset. Mitragynine does engage the opioid system, but not in the same way morphine does. The authors also noted that mitragynine did not cause the morphine-like behavioral changes, such as excitation and Straub’s tail reaction, in their earlier work.

What it means

For researchers, this shows what a high-purity mitragynine standard makes possible: dissecting receptor mechanisms with selective antagonists, comparing a natural alkaloid against a classical opioid, and probing how opioid receptors work together with the descending noradrenergic and serotonergic pain pathways. The same approach could extend to studies of other receptor systems, new analgesic candidates with distinct receptor profiles, and the pharmacology of related plant alkaloids. These findings come from mouse experiments with direct brain administration, so they are a mechanistic foundation, not a clinical conclusion.

 

Interested in our Mitragynine product for your research? Visit our Mitragynine product page: https://www.markherb.com/mitragynine

 

Source: Thongpradichote S, Matsumoto K, Tohda M, Takayama H, Aimi N, Sakai S, Watanabe H. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. Life Sciences, 62(16):1371–1378, 1998.


Editorial Team:

Rafi Rif'atul Rizki, S.I.Kom.